This study suggests that the use of acetylcholinesterase inhibitors, used to improve the quality of life in Alzheimer's patients, may reduce the incidence of age-related macular degeneration in patients with Alzheimer’s by 6%. Randomized clinical trials would be necessary to truly evaluate any cause-and-effect relationship.
No comments:
Post a Comment
Leave a Comment or Question: